Plain-English translation of NCT06026189 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new urine test that can detect urinary tract cancer in patients who have microscopic blood in their urine (blood that is only visible under a microscope). The goal is to see whether using this urine test first can help doctors avoid giving some patients unnecessary, uncomfortable bladder procedures. The urine test has shown very strong results in earlier research, correctly identifying cancer in more than 90% of cases.
Right now, almost all patients with microscopic blood in their urine undergo invasive bladder procedures and radiation scans, even though only 2–5% actually have cancer. This trial exists to see whether the urine test can safely identify which patients truly need these procedures and which ones don't, reducing unnecessary stress, discomfort, radiation exposure, and healthcare costs.
You likely qualify if…
You likely don't qualify if…
Depending on which group you are assigned to, you will either have the standard care (a cystoscopy procedure to look inside your bladder and imaging of your upper urinary tract), or you will first provide a urine sample for the new test. If your urine test is abnormal, you will then have the same standard procedures. The trial will also track your quality of life, comfort level, and healthcare costs throughout the study.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Netherlands
Erasmus Medical Center
Enrollment target
~1,100 participants
Started
May 2023
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in September 2023.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.